Financhill
Buy
54

EVAX Quote, Financials, Valuation and Earnings

Last price:
$2.63
Seasonality move :
-5.59%
Day range:
$2.40 - $2.77
52-week range:
$1.20 - $20.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.84x
P/B ratio:
127.87x
Volume:
356.3K
Avg. volume:
87.2K
1-year change:
-86.27%
Market cap:
$16.6M
Revenue:
$3.3M
EPS (TTM):
-$2.80

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EVAX
Evaxion AS
$60K -$0.71 -59.42% -91.42% $13.25
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -91.39% -8.33% $1.58
ASND
Ascendis Pharma AS
$107.9M -$1.71 292.42% -21.89% $224.30
CLLS
Cellectis SA
$13.8M -- 36.24% -100% $5.60
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.99% $18.41
NVO
Novo Nordisk AS
$11.9B $0.92 19.3% 36.74% $89.76
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EVAX
Evaxion AS
$2.63 $13.25 $16.6M -- $0.00 0% 0.84x
ADAP
Adaptimmune Therapeutics PLC
$0.27 $1.58 $71.9M -- $0.00 0% 0.39x
ASND
Ascendis Pharma AS
$159.24 $224.30 $9.6B -- $0.00 0% 23.72x
CLLS
Cellectis SA
$1.41 $5.60 $141.4M -- $0.00 0% 2.89x
DBVT
DBV Technologies SA
$9.35 $18.41 $255.7M -- $0.00 0% --
NVO
Novo Nordisk AS
$68.60 $89.76 $304.8B 20.32x $1.10 2.36% 7.01x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EVAX
Evaxion AS
-- -0.376 -- 2.80x
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.631 50.03% 1.57x
ASND
Ascendis Pharma AS
128.87% 0.179 9.75% 0.67x
CLLS
Cellectis SA
30.41% 0.907 56.64% 1.64x
DBVT
DBV Technologies SA
-- -3.919 -- --
NVO
Novo Nordisk AS
46.15% 1.792 5.59% 0.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EVAX
Evaxion AS
-- -$1.7M -238.97% -- -54.59% --
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
ASND
Ascendis Pharma AS
$87.8M -$109.7M -59.13% -880.05% -48.32% -$90.9M
CLLS
Cellectis SA
$8.6M -$14.2M -35.55% -49.15% -152.19% -$17.6M
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B

Evaxion AS vs. Competitors

  • Which has Higher Returns EVAX or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -64.14% compared to Evaxion AS's net margin of -653.18%. Evaxion AS's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion AS
    -- -$0.40 $74K
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About EVAX or ADAP?

    Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 403.8%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 481.43%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Evaxion AS, analysts believe Adaptimmune Therapeutics PLC is more attractive than Evaxion AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion AS
    1 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 3 0
  • Is EVAX or ADAP More Risky?

    Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.

  • Which is a Better Dividend Stock EVAX or ADAP?

    Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or ADAP?

    Evaxion AS quarterly revenues are $3M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Evaxion AS's net income of -$1.9M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Evaxion AS's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 0.84x versus 0.39x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion AS
    0.84x -- $3M -$1.9M
    ADAP
    Adaptimmune Therapeutics PLC
    0.39x -- $7.3M -$47.6M
  • Which has Higher Returns EVAX or ASND?

    Ascendis Pharma AS has a net margin of -64.14% compared to Evaxion AS's net margin of -93.73%. Evaxion AS's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion AS
    -- -$0.40 $74K
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About EVAX or ASND?

    Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 403.8%. On the other hand Ascendis Pharma AS has an analysts' consensus of $224.30 which suggests that it could grow by 40.86%. Given that Evaxion AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion AS
    1 0 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is EVAX or ASND More Risky?

    Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

  • Which is a Better Dividend Stock EVAX or ASND?

    Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or ASND?

    Evaxion AS quarterly revenues are $3M, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Evaxion AS's net income of -$1.9M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Evaxion AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 0.84x versus 23.72x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion AS
    0.84x -- $3M -$1.9M
    ASND
    Ascendis Pharma AS
    23.72x -- $106.2M -$99.6M
  • Which has Higher Returns EVAX or CLLS?

    Cellectis SA has a net margin of -64.14% compared to Evaxion AS's net margin of -170.14%. Evaxion AS's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion AS
    -- -$0.40 $74K
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
  • What do Analysts Say About EVAX or CLLS?

    Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 403.8%. On the other hand Cellectis SA has an analysts' consensus of $5.60 which suggests that it could grow by 297.16%. Given that Evaxion AS has higher upside potential than Cellectis SA, analysts believe Evaxion AS is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion AS
    1 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is EVAX or CLLS More Risky?

    Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

  • Which is a Better Dividend Stock EVAX or CLLS?

    Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or CLLS?

    Evaxion AS quarterly revenues are $3M, which are smaller than Cellectis SA quarterly revenues of $10.7M. Evaxion AS's net income of -$1.9M is higher than Cellectis SA's net income of -$18.1M. Notably, Evaxion AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 0.84x versus 2.89x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion AS
    0.84x -- $3M -$1.9M
    CLLS
    Cellectis SA
    2.89x -- $10.7M -$18.1M
  • Which has Higher Returns EVAX or DBVT?

    DBV Technologies SA has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion AS
    -- -$0.40 $74K
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About EVAX or DBVT?

    Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 403.8%. On the other hand DBV Technologies SA has an analysts' consensus of $18.41 which suggests that it could grow by 96.89%. Given that Evaxion AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion AS is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion AS
    1 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is EVAX or DBVT More Risky?

    Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

  • Which is a Better Dividend Stock EVAX or DBVT?

    Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or DBVT?

    Evaxion AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion AS's net income of -$1.9M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Evaxion AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 0.84x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion AS
    0.84x -- $3M -$1.9M
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns EVAX or NVO?

    Novo Nordisk AS has a net margin of -64.14% compared to Evaxion AS's net margin of 37.18%. Evaxion AS's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion AS
    -- -$0.40 $74K
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About EVAX or NVO?

    Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 403.8%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 30.85%. Given that Evaxion AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion AS is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion AS
    1 0 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is EVAX or NVO More Risky?

    Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

  • Which is a Better Dividend Stock EVAX or NVO?

    Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.36% to investors and pays a quarterly dividend of $1.10 per share. Evaxion AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios EVAX or NVO?

    Evaxion AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Evaxion AS's net income of -$1.9M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Evaxion AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 20.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 0.84x versus 7.01x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion AS
    0.84x -- $3M -$1.9M
    NVO
    Novo Nordisk AS
    7.01x 20.32x $11B $4.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
80
SBET alert for May 29

SharpLink Gaming [SBET] is up 48.83% over the past day.

Buy
100
BOX alert for May 29

Box [BOX] is down 0.22% over the past day.

Sell
22
OKTA alert for May 29

Okta [OKTA] is up 0.8% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock